Bright Minds Biosciences Inc. Common Stock (DRUG)

About DRUG

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmenta…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

26

Website

brightmindsbio.com/

Fundamentals

1-day range

$72.16$74.32

Market cap

$792.81M

P/E (trailing)

—

P/E (forward)

-12.35

EPS (trailing)

$-3.40

Dividend yield

—

Beta

1.99

Avg. volume

291.8K

Forecasts

3 analyst ratings

Bright Minds Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• DRUG

  Bright Minds Biosciences Inc. Common Stock

  $72.74

  ▼ 2.41%
  Market cap $792.81MP/E —
  $53.99$170
• CLYM

  Climb Bio Inc. Common Stock

  $14.56

  ▼ 3.32%
  Market cap $801.68MP/E —
  $1.54$18.33
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $805.29MP/E —
  $32.77$124.82
• PHAR

  Pharming Group N.V. ADS each representing 10 ordinary shares

  $11.7

  ▼ 0.68%
  Market cap $766.28MP/E 88.15
  $0.8338$1.82
• KURA

  Kura Oncology Inc. Common Stock

  $12.65

  ▼ 4.06%
  Market cap $823.83MP/E —
  $7.36$13.9
• CYRX

  CryoPort Inc. Common Stock

  $16.08

  ▼ 2.96%
  Market cap $741.42MP/E —
• ACRS

  Aclaris Therapeutics Inc. Common Stock

  $6.01

  ▼ 2.44%
  Market cap $850.55MP/E —
  $1.74$6.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
  benzinga · 8/19/2026
• HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
  Benzinga · 8/19/2026
• BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
  Benzinga · 8/17/2026
• Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
  Yahoo · 8/10/2026
• Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials
  SeekingAlpha · 8/10/2026

• Cormorant Asset Management, LP · April 28, 2026 · Sale

  109.3K @ $89.5

Institutional Ownership

March 31, 2026

Total shares held

9.11M

Total value held

$664.32M

Institutional holders

89